Copycat Biosimilar Drugs As Effective As Expensive Biologics, Study Finds
“This is the $1 billion question — are the biosimilar versions comparable? And we found, in just about every outcome examined, that the biosimilars fare very well,” one of the study's authors says.
Stat:
Some Biosimilars Are Just As Good As Some Pricey Biologics
A new study suggests that a group of biosimilar drugs, which are used to treat such afflictions as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, appear as safe and effective as their more expensive brand-name counterparts, which are known as biologics. A biosimilar drug is a nearly identical variant of a biologic and is expected to provide the same result in patients. The analysis arrives as the US health care system, which is increasingly overwhelmed by high-priced medicines, looks toward biosimilars to provide savings. In the United States, where regulators have approved just two such drugs, some estimates say prices will be 20 percent to 30 percent less than the cost of biologics. (Silverman, 8/1)
NPR:
FDA-Approved Knock-Offs Of Biotech Drugs Could Safely Save Big Bucks
Copycat versions of biotech drugs work just as well as the originals and cost a lot less, according to an analysis of studies of the medicines. The analysis by researchers at Johns Hopkins Bloomberg School of Public Health finds that so-called biosimilars — medications that are meant to mimic, and compete with, complex and expensive biotech drugs — perform as well as the brand-name versions. (Kodjak, 8/1)
Kaiser Health News:
Study Bodes Well For Biosimilars But Highlights Need For More Research
Research released Monday finds comparable safety and efficacy for one type of biosimilar drugs, complex medicines intended to be near-copies of some of the most costly prescription drugs on the market, but highlights the need for more information on the products. In the absence of generic alternatives to these pricey treatments, called biologics, biosimilar drugs hold great promise for U.S. patients and their wallets. (Lupkin, 8/1)
